# Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium

> **NCT00870649** · PHASE3 · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 250 (actual)

## Conditions studied

- Urinary Schistosomiasis
- Schistosoma Haematobium

## Interventions

- **BIOLOGICAL:** Bilhvax vaccine (Sh28GST)
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00870649
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2012-06
- **Final completion:** 2012-12
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00870649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00870649, "Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00870649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*